<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Huang, Annie</style></author><author><style face="normal" font="default" size="100%">Fernandez Vasquez, Jennifer L.</style></author><author><style face="normal" font="default" size="100%">Yeager, Catherine A.</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Esketamine: A Possible Adjunctive Therapy for Treatment Resistant Depression</style></title><secondary-title><style face="normal" font="default" size="100%">The Journal of the American Board of Family
                Medicine</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2025-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">1120-1122</style></pages><doi><style  face="normal" font="default" size="100%">10.3122/jabfm.2025.250369R0</style></doi><volume><style face="normal" font="default" size="100%">38</style></volume><issue><style face="normal" font="default" size="100%">6</style></issue><abstract><style  face="normal" font="default" size="100%">If available in one’s practice area, augmenting current medication therapy with esketamine results in greater rates of remission for treatment resistant depression as compared with quetiapine1.</style></abstract></record></records></xml>